Aesis Therapeutics is a pharmaceutical company founded in 2013 focused on developing innovative oncology drugs. It has two drug candidates in development targeting two types of cancer with unmet needs: NAX035 for malignant mesothelioma and NAX014 for HER2-positive breast cancer. The company has raised €0.485 million in seed funding and plans to raise €2.42 million and €3.675 million in subsequent funding rounds to advance the drug candidates through Phase I clinical trials over three years. Successful completion of Phase I trials could result in a potential exit value of €10 million plus milestones.